Dr. Branimir I. Sikic, MD is a Hematology / Oncology Specialist - Hematologist (Blood) practicing in Palo Alto, CA
He has not yet shared a personalized biography with Doctor.com.
University | Degree | Focus | Graduated |
---|---|---|---|
University of Chicago, Pritzker School of Medicine, Chicago Il | Other Degree | 1972 |
Institution | Focus | Year |
---|---|---|
Internship - Georgetown University Hospital | 1973 | |
Residency - Medstar-Georgetown Medical Center, Internal Medicine | Not Specified | |
Residency - Georgetown University Hospital | 1975 | |
Fellowship - National Cancer Institute | 1978 |
Certification | Cert. Body | Year |
---|---|---|
Sub-Specialty: Medical Oncology | Internal Medicine | 1979 |
Internal medicine | Internal Medicine | 1975 |
Internal medicine Sub-Specialty: Medical Oncology | Internal Medicine | Not Specified |
Publication | Publisher | Title | Published |
---|---|---|---|
Other Publication | CLINICAL TRIALS | Clinical trial designs for testing biomarker-based personalized therapies | 2012 |
Other Publication | NEW ENGLAND JOURNAL OF MEDICINE | NFKBIA Deletion in Glioblastomas. | 2011 |
Other Publication | MOLECULAR CANCER THERAPEUTICS | Expression and Silencing of the Microtubule-Associated Protein Tau in Breast Cancer Cells | 2010 |
Other Publication | JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | A Network Model of a Cooperative Genetic Landscape in Brain Tumors | 2009 |
Other Publication | CLINICAL CANCER RESEARCH | A Phase II Study of Gefitinib, 5-Fluorouracil | 2008 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Differential gene expression patterns and interaction networks in BCR-ABL | 2007 |
Other Publication | GENES CHROMOSOMES & CANCER | Regional activation of chromosomal arm 7q with | 2006 |
Other Publication | INVESTIGATIONAL NEW DRUGS | Phase I study of gefitinib, oxaliplatin | 2006 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Tumor necrosis factor-alpha | 2006 |
Other Publication | PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O | Gene expression profiling differentiates germ cell tumors from other cancers | 2005 |
Other Publication | CANCER RESEARCH | Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell | 2005 |
Other Publication | CANCER RESEARCH | Functional network analysis reveals extended gliomagenesis pathway maps | 2005 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Phase II study of gefitinib, fluorouracil | 2005 |
Other Publication | CANCER RESEARCH | High-resolution genome-wide mapping of genetic alterations in human glial brain tumors | 2005 |
Other Publication | BLOOD | Gene expression profiles at diagnosis | 2004 |
Other Publication | MOLECULAR PHARMACOLOGY | CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human | 2004 |
Other Publication | Journal of experimental therapeutics & oncology | Modulation of resistance to idarubicin by the cyclosporin PSC 833 | 2003 |
Other Publication | GENES CHROMOSOMES & CANCER | Preferential expression of a mutant allele of the amplified MDR1 | 2002 |
Other Publication | BRITISH JOURNAL OF CANCER | MDR1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells | 2000 |
Other Publication | MOLECULAR PHARMACOLOGY | Loss of cyclosporin | 2000 |
Other Publication | ONCOLOGY-NEW YORK | Modulation of multidrug resistance: A paradigm for translational clinical research | 1999 |
Other Publication | CANCER CHEMOTHERAPY AND PHARMACOLOGY | Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein | 1997 |
Other Publication | JOURNAL OF BIOLOGICAL CHEMISTRY | Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype | 1997 |
Other Publication | CANCER RESEARCH | Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel | 1996 |
Other Publication | JOURNAL OF THE NATIONAL CANCER INSTITUTE | DECREASED MUTATION-RATE FOR CELLULAR | 1995 |
Other Publication | Cancer treatment and research | The reversal of multidrug resistance. | 1995 |
Other Publication | CANCER RESEARCH | PREVALENCE OF MULTIDRUG | 1994 |
Other Publication | JOURNAL OF THE NATIONAL CANCER INSTITUTE | MUTATION-RATES AND MECHANISMS OF RESISTANCE TO ETOPOSIDE DETERMINED FROM FLUCTUATION ANALYSIS | 1994 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE | 1994 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | MODULATION OF MULTIDRUG-RESISTANCE - AT THE THRESHOLD | 1993 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | PHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE | 1992 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | ALTERATION OF ETOPOSIDE PHARMACOKINETICS AND PHARMACODYNAMICS BY CYCLOSPORINE IN A PHASE | 1992 |
Other Publication | BLOOD | MULTIDRUG RESISTANCE | 1991 |
Other Publication | CANCER RESEARCH | MULTIDRUG (PLEIOTROPIC) RESISTANCE IN DOXORUBICIN | 1985 |
Other Publication | SCIENCE | DISSOCIATION OF ANTITUMOR POTENCY FROM ANTHRACYCLINE CARDIOTOXICITY IN A DOXORUBICIN ANALOG | 1985 |
Other Publication | CANCER RESEARCH | DEVELOPMENT AND CHARACTERIZATION OF A HUMAN SARCOMA CELL-LINE, MES-SA, SENSITIVE TO MULTIPLE-DRUGS | 1983 |
Other Publication | CANCER TREATMENT REPORTS | IMPROVED THERAPEUTIC INDEX OF BLEOMYCIN WHEN ADMINISTERED BY CONTINUOUS INFUSION IN MICE | 1978 |
Other Publication | CANCER RESEARCH | QUANTIFICATION OF BLEOMYCIN PULMONARY TOXICITY IN MICE BY CHANGES IN LUNG HYDROXYPROLINE CONTENT | 1978 |
Other Publication | INVESTIGATIONAL NEW DRUGS | Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 | 2012 |
Other Publication | INVESTIGATIONAL NEW DRUGS | A phase I trial of vandetanib combined with capecitabine | 2012 |
Other Publication | INVESTIGATIONAL NEW DRUGS | Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine | 2011 |
Other Publication | PEDIATRIC BLOOD & CANCER | Phase I Study of Valspodar | 2010 |
Other Publication | ANNALS OF ONCOLOGY | Phase I and pharmacokinetic study of lexatumumab | 2010 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Analysis of phase II studies on targeted agents and subsequent phase III trials | 2008 |
Other Publication | Ueda, S. M., Kapp, D. S., Sugiyama, V. E., Stave, C., Shin, J. Y., Mon | Predictors for success in a phase III trial | 2007 |
Other Publication | Methods in molecular biology (Clifton, N.J.) | Integrated high-resolution genome-wide analysis of gene dosage | 2007 |
Other Publication | Lacayo, N. J., O'Brien, M., Jain, S., Meshinchi, S., Yu, R., Juric, D. | Gene expression profiling predicts outcome in de novo acute myeloid leukemia | 2006 |
Other Publication | Juric, D., Lacayo, N. J., Ramsey, M. C., Racevskis, J., Wiernik, P. H. | Differential gene expression patterns and interaction networks in BCR | 2006 |
Other Publication | CANCER INVESTIGATION | A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel | 2006 |
Other Publication | CLINICAL CANCER RESEARCH | Multidrug resistance and stem cells in acute myeloid leukemia | 2006 |
Other Publication | ANNALS OF ONCOLOGY | A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833) | 2005 |
Other Publication | Lacayo, N., Meshinchi, S., Raimondi, S., Saraiya, C., O'Brien, M., Yu, | Gene expression profiling and FLT3 status correlate with outcome in de novo acute myeloid leukemia | 2005 |
Other Publication | INVESTIGATIONAL NEW DRUGS | A phase I trial of aprinocarsen (ISIS 3521 | 2005 |
Other Publication | CLINICAL LUNG CANCER | Activity of novel cytotoxic agents in lung cancer: Epothilones and topoisomerase I inhibitors | 2005 |
Other Publication | Fisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., Fitzg | A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies | 2005 |
Other Publication | JOURNAL OF MOLECULAR DIAGNOSTICS | Amplification of whole tumor genomes | 2005 |
Other Publication | BMC GENOMICS | A method for detecting and correcting feature misidentification on expression microarrays | 2004 |
Other Publication | Bulletin du cancer | Resistance to microtubule | 2004 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Mitoxantrone, etoposide | 2004 |
Other Publication | LANCET ONCOLOGY | Genomics-based hypothesis generation | 2004 |
Other Publication | CANCER | A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha | 2004 |
Other Publication | Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J | A phase II study of gefitinib in combination with FOLFOX-4 | 2003 |
Other Publication | CLINICAL CANCER RESEARCH | Phase I and pharmacokinetic study of BMS-188797, a new taxane analog | 2003 |
Other Publication | MOLECULAR BIOLOGY OF THE CELL | Gene expression patterns in ovarian carcinomas | 2003 |
Other Publication | BREAST CANCER RESEARCH AND TREATMENT | Phase I trial of uracil-ftorafur, leucovorin | 2003 |
Other Publication | Balzer, B., Schaner, M., Ross, D., Montgomery, K., Teng, N., Sikic, B. | Protein expression study of ovarian surface epithelial neoplasms using tissue microarray analysis | 2003 |
Other Publication | JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL | Rapid determination of PEGylated liposomal doxorubicin | 2002 |
Other Publication | Fisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., | A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin | 2002 |
Other Publication | JOURNAL OF THE NATIONAL CANCER INSTITUTE | Re: Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer | 2002 |
Other Publication | LEUKEMIA | Pharmacokinetic interactions of cyclosporine with etoposide | 2002 |
Other Publication | Lum, B. L., Chin, D. L., Cho, C. D., Advani, R., Fisher, G. A., Halsey | The effect of oral valspodar (psc 833), a modulator of multidrug resistance | 2002 |
Other Publication | MOLECULAR CANCER THERAPEUTICS | Conservation of the class I beta-tubulin gene in human populations | 2002 |
Other Publication | CLINICAL CANCER RESEARCH | Motexafin gadolinium: A redox active drug that enhances the efficacy of bleomycin and doxorubicin | 2001 |
Other Publication | Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litc | A phase I trial of doxorubicin, paclitaxel | 2001 |
Other Publication | NATURE GENETICS | Dominant effector genetics in mammalian cells | 2001 |
Other Publication | FRONTIERS IN BIOSCIENCE | Clinical studies of antisense therapy in cancer | 2000 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Mitoxantrone, etoposide | 2000 |
Other Publication | ANTI-CANCER DRUGS | Decreased cortisol secretion by adrenal gl | 2000 |
Other Publication | CANCER CHEMOTHERAPY AND PHARMACOLOGY | Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P | 2000 |
Other Publication | Greenberg, P., Advani, R., Tallman, M., Letendre, L., Saba, H., Dugan, | Treatment of refractory | 1999 |
Other Publication | CLINICAL CANCER RESEARCH | Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521 | 1999 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport | 1999 |
Other Publication | BLOOD | Treatment of refractory | 1999 |
Other Publication | Tallman, M. S., Lee, S., Sikic, B. I., Paietta, E., Wiernik, P. H., Be | Mitoxantrone, etoposide | 1999 |
Other Publication | Advani, R., Visani, G., Milligan, D., Saba, H., Tallman, M., Rowe, J. | Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide | 1999 |
Other Publication | Sikic, B. I. | New approaches in cancer treatment | 1999 |
Other Publication | JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein | 1998 |
Other Publication | CANCER CHEMOTHERAPY AND PHARMACOLOGY | Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits | 1998 |
Other Publication | SEMINARS IN HEMATOLOGY | Pharmacologic approaches to reversing multidrug resistance | 1997 |
Other Publication | PHARMACOTHERAPY | Validation of a limited sampling model to determine etoposide area under the curve | 1997 |
Other Publication | ANNALS OF ONCOLOGY | Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine | 1997 |
Other Publication | BRITISH JOURNAL OF CANCER | Spontaneous overexpression of the long form of the bcl | 1997 |
Other Publication | CANCER CHEMOTHERAPY AND PHARMACOLOGY | Differential single- versus double | 1996 |
Other Publication | EUROPEAN JOURNAL OF CANCER | Pharmacological considerations in the modulation of multidrug resistance | 1996 |
Other Publication | AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY | Doxorubicin selection for MDR1 | 1996 |
Other Publication | Lum, B. L., Synold, T. W., Lane, K., Charnick, S. B., Sikic, B. I. | Neural network (NN) | 1996 |
Other Publication | CELL MOTILITY AND THE CYTOSKELETON | Differential expression of tubulin isotypes during the cell cycle | 1996 |
Other Publication | CANCER CHEMOTHERAPY AND PHARMACOLOGY | Effect of different mathematical methods on etoposide area under the curve estimations | 1996 |
Other Publication | LEUKEMIA | GLUTATHIONE-S-TRANSFERASE-PI, GLUTATHIONE-S-TRANSFERASE-ALPHA | 1995 |
Other Publication | ANTI-CANCER DRUGS | CYCLOSPORINE-A INCREASES SERUM CORTISOL-LEVELS IN RABBITS | 1995 |
Other Publication | BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH | INHIBITION OF LYSOSOMAL ACID SPHINGOMYELINASE BY AGENTS WHICH REVERSE MULTIDRUG-RESISTANCE | 1995 |
Other Publication | Hematology/oncology clinics of North America | Drug resistance in clinical oncology and hematology. Introduction. | 1995 |
Other Publication | HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | CLINICAL-STUDIES WITH MODULATORS OF MULTIDRUG-RESISTANCE | 1995 |
Other Publication | ONCOLOGY RESEARCH | Novel mechanism of resistance to paclitaxel (Taxol(R)) | 1995 |
Other Publication | MOLECULAR PHARMACOLOGY | EVIDENCE FOR TRANSCRIPTIONAL CONTROL OF HUMAN MDR1 GENE-EXPRESSION BY VERAPAMIL IN MULTIDRUG | 1995 |
Other Publication | INTERNATIONAL JOURNAL OF ONCOLOGY | ANALYSIS OF INTRACELLULAR RETENTION OF MORPHOLINYL ANTHRACYCLINES IN MULTIDRUG-RESISTANT CANCER | 1994 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | MULTIDRUG-RESISTANCE IN LYMPHOMAS | 1994 |
Other Publication | CANCER RESEARCH | VOLUME-ACTIVATED CHLORIDE CURRENT IS NOT RELATED TO P-GLYCOPROTEIN OVEREXPRESSION | 1994 |
Other Publication | BRITISH JOURNAL OF CANCER | METABOLIC CONVERSION OF METHOXYMORPHOLINYL DOXORUBICIN - FROM A DNA STRAND BREAKER TO A DNA CROSS | 1994 |
Other Publication | LEUKEMIA | MDR1 GENE-EXPRESSION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIAS AND LYMPHOMAS | 1994 |
Other Publication | BLOOD | CYCLOSPORINE A AND CYCLOSPORINE SDZ PSC 833 ENHANCE ANTI-CD5 RICIN A | 1994 |
Other Publication | Cancer treatment and research | Clinical reversal of multidrug resistance. | 1994 |
Other Publication | LEYLANDJONES, B., Dalton, W., Fisher, G. A., Sikic, B. I. | REVERSAL OF MULTIDRUG-RESISTANCE TO CANCER-CHEMOTHERAPY | 1993 |
Other Publication | Lum, B. L., Fisher, G. A., BROPHY, N. A., Yahanda, A. M., ADLER, K. M. | CLINICAL-TRIALS OF MODULATION OF MULTIDRUG | 1993 |
Other Publication | CANCER CHEMOTHERAPY AND PHARMACOLOGY | EFFECTS OF THE METHOXYMORPHOLINO DERIVATIVE OF DOXORUBICIN AND ITS BIOACTIVATED FORM VERSUS | 1993 |
Other Publication | PHARMACOTHERAPY | MOLECULAR TARGETS IN ONCOLOGY - IMPLICATIONS OF THE MULTIDRUG RESISTANCE GENE | 1993 |
Other Publication | Fisher, G. A., BROPHY, N. A., Yahanda, A. M., Adler, K. A., Lum, B. L. | THE MODULATION OF MULTIDRUG-RESISTANCE - CLINICAL-STUDIES AT STANFORD | 1993 |
Other Publication | JOURNAL OF THE NATIONAL CANCER INSTITUTE | CHARACTERIZATION OF COVALENT DNA | 1992 |
Other Publication | EXPERIMENTAL HEMATOLOGY | USE OF ETOPOSIDE IN COMBINATION WITH CYCLOSPORINE FOR PURGING MULTIDRUG-RESISTANT LEUKEMIC | 1992 |
Other Publication | CANCER RESEARCH | ROLE OF CYTOCHROME-P | 1992 |
Other Publication | BRITISH JOURNAL OF HAEMATOLOGY | EXPRESSION OF MULTIDRUG RESISTANCE GENE MDR1 MESSENGER-RNA IN A SUBSET OF NORMAL BONE-MARROW CELLS | 1992 |
Other Publication | Progress in clinical and biological research | Use of etoposide in combination with cyclosporine | 1992 |
Other Publication | Sikic, B. I. | COMBINED CHEMOTHERAPY AND RADIOTHERAPY FOR ADVANCED-STAGE CARCINOMAS OF THE CERVIX | 1992 |
Other Publication | Progress in clinical and biological research | Purging multidrug resistant cells from bone marrow. | |
Other Publication | CLINICAL TRIALS | Clinical trial designs for testing biomarker-based persolized therapies | 2012 |
Other Publication | NEW ENGLAND JOURL OF MEDICINE | NFKBIA Deletion in Glioblastomas. | 2011 |
Other Publication | JAMA-JOURL OF THE AMERICAN MEDICAL ASSOCIATION | A Network Model of a Cooperative Genetic Landscape in Brain Tumors | 2009 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Differential gene expression patterns and interaction networks in BCR-ABL | 2007 |
Other Publication | GENES CHROMOSOMES & CANCER | Regiol activation of chromosomal arm 7q with | 2006 |
Other Publication | INVESTIGATIOL NEW DRUGS | Phase I study of gefitinib, oxaliplatin | 2006 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Tumor necrosis factor-alpha | 2006 |
Other Publication | PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM | Gene expression profiling differentiates germ cell tumors from other cancers | 2005 |
Other Publication | CANCER RESEARCH | Functiol network alysis reveals extended gliomagenesis pathway maps | 2005 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Phase II study of gefitinib, fluorouracil | 2005 |
Other Publication | Jourl of experimental therapeutics & oncology | Modulation of resistance to idarubicin by the cyclosporin PSC 833 | 2003 |
Other Publication | BRITISH JOURL OF CANCER | MDR1 activation is the predomint resistance mechanism selected by vinblastine in MES-SA cells | 2000 |
Other Publication | ONCOLOGY-NEW YORK | Modulation of multidrug resistance: A paradigm for translatiol clinical research | 1999 |
Other Publication | JOURL OF BIOLOGICAL CHEMISTRY | Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype | 1997 |
Other Publication | JOURL OF THE TIOL CANCER INSTITUTE | DECREASED MUTATION-RATE FOR CELLULAR | 1995 |
Other Publication | JOURL OF THE TIOL CANCER INSTITUTE | MUTATION-RATES AND MECHANISMS OF RESISTANCE TO ETOPOSIDE DETERMINED FROM FLUCTUATION ALYSIS | 1994 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE | 1994 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | MODULATION OF MULTIDRUG-RESISTANCE - AT THE THRESHOLD | 1993 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | PHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE | 1992 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | ALTERATION OF ETOPOSIDE PHARMACOKINETICS AND PHARMACODYMICS BY CYCLOSPORINE IN A PHASE | 1992 |
Other Publication | SCIENCE | DISSOCIATION OF ANTITUMOR POTENCY FROM ANTHRACYCLINE CARDIOTOXICITY IN A DOXORUBICIN ALOG | 1985 |
Other Publication | CANCER RESEARCH | QUANTIFICATION OF BLEOMYCIN PULMORY TOXICITY IN MICE BY CHANGES IN LUNG HYDROXYPROLINE CONTENT | 1978 |
Other Publication | INVESTIGATIOL NEW DRUGS | Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 | 2012 |
Other Publication | INVESTIGATIOL NEW DRUGS | A phase I trial of vandetanib combined with capecitabine | 2012 |
Other Publication | INVESTIGATIOL NEW DRUGS | Phase I trial of oblimersen (GesenseA (R)) and gemcitabine in refractory and advanced maligncies | 2011 |
Other Publication | ANLS OF ONCOLOGY | Phase I and pharmacokinetic study of lexatumumab | 2010 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Alysis of phase II studies on targeted agents and subsequent phase III trials | 2008 |
Other Publication | Ueda, S. M., Kapp, D. S., Sugiyama, V. E., Stave, C., Shin, J. Y., Mon | Predictors for success in a phase III trial | 2007 |
Other Publication | Methods in molecular biology (Clifton, N.J.) | Integrated high-resolution genome-wide alysis of gene dosage | 2007 |
Other Publication | ANLS OF ONCOLOGY | A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833) | 2005 |
Other Publication | INVESTIGATIOL NEW DRUGS | A phase I trial of aprinocarsen (ISIS 3521 | 2005 |
Other Publication | Fisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., Fitzg | A phase I trial of oblimersen and gemcitabine in refractory and advanced maligncies | 2005 |
Other Publication | JOURL OF MOLECULAR DIAGNOSTICS | Amplification of whole tumor genomes | 2005 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Mitoxantrone, etoposide | 2004 |
Other Publication | CANCER | A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kise C alpha | 2004 |
Other Publication | Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J | A phase II study of gefitinib in combition with FOLFOX-4 | 2003 |
Other Publication | CLINICAL CANCER RESEARCH | Phase I and pharmacokinetic study of BMS-188797, a new taxane alog | 2003 |
Other Publication | Balzer, B., Schaner, M., Ross, D., Montgomery, K., Teng, N., Sikic, B. | Protein expression study of ovarian surface epithelial neoplasms using tissue microarray alysis | 2003 |
Other Publication | JOURL OF CHROMATOGRAPHY B-ALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND | Rapid determition of PEGylated liposomal doxorubicin | 2002 |
Other Publication | Fisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., | A phase I study of ZD 1839 (Iressa) in combition with oxaliplatin | 2002 |
Other Publication | JOURL OF THE TIOL CANCER INSTITUTE | Re: Genetic alysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer | 2002 |
Other Publication | TURE GENETICS | Domint effector genetics in mammalian cells | 2001 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Mitoxantrone, etoposide | 2000 |
Other Publication | ANTI-CANCER DRUGS | Decreased cortisol secretion by adrel gl | 2000 |
Other Publication | CANCER CHEMOTHERAPY AND PHARMACOLOGY | Effect of high-dose cyclosporine on etoposide pharmacodymics in a trial to reverse P-glycoprotein | 2000 |
Other Publication | CLINICAL CANCER RESEARCH | Phase I study of an antisense oligonucleotide to protein kise C-alpha (ISIS 3521 | 1999 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Mechanisms of action of and resistance to antitubulin agents: Microtubule dymics, drug transport | 1999 |
Other Publication | BLOOD | Treatment of refractory | 1999 |
Other Publication | JOURL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein | 1998 |
Other Publication | SEMIRS IN HEMATOLOGY | Pharmacologic approaches to reversing multidrug resistance | 1997 |
Other Publication | ANLS OF ONCOLOGY | Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine | 1997 |
Other Publication | BRITISH JOURL OF CANCER | Spontaneous overexpression of the long form of the bcl | 1997 |
Other Publication | CANCER CHEMOTHERAPY AND PHARMACOLOGY | Differential single- versus double | 1996 |
Other Publication | EUROPEAN JOURL OF CANCER | Pharmacological considerations in the modulation of multidrug resistance | 1996 |
Other Publication | AMERICAN JOURL OF PHYSIOLOGY-CELL PHYSIOLOGY | Doxorubicin selection for MDR1 | 1996 |
Other Publication | BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH | INHIBITION OF LYSOSOMAL ACID SPHINGOMYELISE BY AGENTS WHICH REVERSE MULTIDRUG-RESISTANCE | 1995 |
Other Publication | MOLECULAR PHARMACOLOGY | EVIDENCE FOR TRANSCRIPTIOL CONTROL OF HUMAN MDR1 GENE-EXPRESSION BY VERAPAMIL IN MULTIDRUG | 1995 |
Other Publication | INTERTIOL JOURL OF ONCOLOGY | ALYSIS OF INTRACELLULAR RETENTION OF MORPHOLINYL ANTHRACYCLINES IN MULTIDRUG-RESISTANT CANCER | 1994 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | MULTIDRUG-RESISTANCE IN LYMPHOMAS | 1994 |
Other Publication | BRITISH JOURL OF CANCER | METABOLIC CONVERSION OF METHOXYMORPHOLINYL DOXORUBICIN - FROM A D STRAND BREAKER TO A D CROSS | 1994 |
Other Publication | Lum, B. L., Fisher, G. A., BROPHY, N. A., Yahanda, A. M., ADLER, K. M. | CLINICAL-TRIALS OF MODULATION OF MULTIDRUG | 1993 |
Other Publication | JOURL OF THE TIOL CANCER INSTITUTE | CHARACTERIZATION OF COVALENT D-BINDING OF MORPHOLINO AND CYANOMORPHOLINO DERIVATIVES OF DOXORUBICIN | 1992 |
Other Publication | EXPERIMENTAL HEMATOLOGY | USE OF ETOPOSIDE IN COMBITION WITH CYCLOSPORINE FOR PURGING MULTIDRUG-RESISTANT LEUKEMIC | 1992 |
Other Publication | BRITISH JOURL OF HAEMATOLOGY | EXPRESSION OF MULTIDRUG RESISTANCE GENE MDR1 MESSENGER-R IN A SUBSET OF NORMAL BONE-MARROW CELLS | 1992 |
Other Publication | Progress in clinical and biological research | Use of etoposide in combition with cyclosporine | 1992 |
Dr. Branimir I. Sikic, MD has not yet indicated the hospitals that he is affiliated with.
Years In Practice: 44 (started in 1979)
Accepts New Patients: Yes